uniQure (QURE) Cash & Equivalents (2015 - 2026)
uniQure (QURE) posted quarterly Cash & Equivalents of $413.0 million for Q2 2026, up 62.75% year-over-year from $253.8 million in Q2 2025, and up 195.03% quarter-over-quarter from $140.0 million in Q1 2026.
Analysis
uniQure (QURE) Cash & Equivalents (2015 - 2026) Analysis & Trends
uniQure's Cash & Equivalents history runs 12 years deep, the most recent figure standing at $413.0 million for Q2 2026.
- In Q2 2026, Cash & Equivalents rose 62.75% year-over-year to $413.0 million; the TTM figure through Jun 2026 stood at $413.0 million (up 62.75% YoY), while the FY2025 annual figure was $80.2 million, down 49.51% from the prior year.
- Cash & Equivalents for Q2 2026 stood at $413.0 million, up from $140.0 million in the prior quarter.
- The five-year high for Cash & Equivalents was $597.1 million in Q3 2025, with the low at $80.2 million in Q4 2025.
- The 5-year median for Cash & Equivalents is $247.3 million (2024), against an average of $304.2 million.
- The sharpest annual moves came in 2023 and 2025: Cash & Equivalents slumped 70.69% in 2023, then jumped 137.28% in 2025.
- uniQure's Cash & Equivalents stood at $228.0 million in 2022, then climbed by 5.85% to $241.4 million in 2023, then plunged by 34.15% to $158.9 million in 2024, then plunged by 49.51% to $80.2 million in 2025, then soared by 414.74% to $413.0 million in 2026.
- Business Quant data shows QURE's Cash & Equivalents at $413.0 million in Q2 2026, $140.0 million in Q1 2026, and $80.2 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 3.58 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 1.72 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 815.44 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 5.10 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 1.71 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 811.99 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 544.80 Mn |
| 10 | uniQure | 2.95 Bn | 2.95 Bn | 5.49 Mn | 413.03 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 413.03 Mn |
| Mar 31, 2026 | 139.99 Mn |
| Dec 31, 2025 | 80.24 Mn |
| Sep 30, 2025 | 597.06 Mn |
| Jun 30, 2025 | 253.78 Mn |
| Mar 31, 2025 | 217.23 Mn |
| Dec 31, 2024 | 158.93 Mn |
| Sep 30, 2024 | 251.63 Mn |
| Jun 30, 2024 | 287.88 Mn |
| Mar 31, 2024 | 243.06 Mn |
| Dec 31, 2023 | 241.36 Mn |
| Sep 30, 2023 | 229.48 Mn |
| Jun 30, 2023 | 513.60 Mn |
| Mar 31, 2023 | 153.85 Mn |
| Dec 31, 2022 | 228.01 Mn |
| Sep 30, 2022 | 440.31 Mn |
| Jun 30, 2022 | 500.52 Mn |
| Mar 31, 2022 | 524.89 Mn |
| Dec 31, 2021 | 556.26 Mn |
| Sep 30, 2021 | 578.46 Mn |